Melanotan II

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors throughout the body. MC1R activation triggers melanin production for tanning, while MC4R affects sexual arousal and appetite control.

Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide developed at the University of Arizona as a more potent, shorter analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its cyclic structure — incorporating a lactam bridge between positions 4 and 10 — confers enhanced receptor binding affinity, metabolic stability, and broader melanocortin receptor activation compared to the linear Melanotan I. MT-II is a non-selective agonist at MC1R (melanogenesis), MC3R (energy homeostasis), MC4R (appetite, sexual function, erectile response), and MC5R (exocrine secretion), producing a diverse pharmacological profile that extends well beyond skin pigmentation.

The multi-receptor activity of Melanotan II has generated research interest across several therapeutic domains. Its MC1R-mediated tanning effect is the most visible outcome, producing significant melanogenesis and darkening of skin and hair. The MC4R-mediated pro-erectile effect led to the development of bremelanotide (PT-141), a derivative that was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women — the first melanocortin-based drug approved for sexual dysfunction. MT-II's appetite-suppressive effects via MC3R/MC4R have been explored in obesity research, though development for this indication has not advanced to approval. In preclinical studies, melanocortin receptor activation has also demonstrated anti-inflammatory and neuroprotective effects, adding further dimensions to MT-II's pharmacological interest.

Despite its investigational status and lack of regulatory approval for cosmetic tanning, Melanotan II has become widely available through online peptide suppliers and is self-administered subcutaneously by individuals seeking UV-free tanning. This unregulated use raises significant safety concerns: reported adverse effects include nausea, facial flushing, fatigue, changes in existing moles (nevi) that complicate melanoma screening, and priapism from the pro-erectile effect. There are also case reports linking MT-II to melanoma development, though a causal relationship has not been established. The typical self-administration protocol involves a loading phase of 0.25–0.5 mg subcutaneously daily for 1–2 weeks, followed by maintenance dosing of 0.5 mg once or twice weekly. Medical supervision is strongly recommended, and dermatological monitoring of nevi is essential for anyone using melanocortin agonists.

Mechanism of Action

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-MSH with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Unlike the MC1R-selective Melanotan I, MT-II is a non-selective agonist that activates melanocortin receptors MC1R, MC3R, MC4R, and MC5R with varying affinities, producing a broader spectrum of physiological effects. At MC1R on melanocytes, it triggers the same cAMP/PKA/MITF/tyrosinase cascade as Melanotan I, stimulating eumelanin production and skin darkening without UV exposure.

The central nervous system effects of MT-II are mediated primarily through MC3R and MC4R in the hypothalamus. MC4R activation in the paraventricular nucleus (PVN) stimulates pro-opiomelanocortin (POMC) neuronal circuits that suppress appetite and increase energy expenditure through sympathetic nervous system activation. MC4R signaling also activates oxytocinergic pathways in the PVN that project to the spinal cord, mediating erectile function through increased parasympathetic outflow to penile vasculature. This mechanism involves nitric oxide (NO) release from cavernosal endothelium and smooth muscle relaxation via the NO/cGMP pathway, producing the pro-erectile effects that led to development of the related drug bremelanotide. MC3R activation in the arcuate nucleus modulates energy homeostasis and feeding behavior through distinct but overlapping circuits.

The non-selective receptor profile of MT-II accounts for both its broad effects and its side effect profile. MC3R/MC4R activation can produce nausea through area postrema stimulation, facial flushing via peripheral vasodilation, and fatigue. Chronic MC1R stimulation may promote melanocytic nevus darkening. The compound's cyclic structure provides resistance to enzymatic degradation, giving it a longer duration of action than linear melanocortin peptides.

Reconstitution Calculator

Safety Profile

Common side effects include nausea, facial flushing, spontaneous erections, and darkening of moles. Health authorities advise against its use due to serious risks such as the potential to promote melanoma development, kidney dysfunction, and cardiovascular issues. Product quality from unregulated sources is not guaranteed, and its sale is restricted in many countries.

Pharmacokinetic Profile